SG11201507385YA - Method of producing an immunoligan d/paylo ad conjugate by means of a sequence-specific transpeptidase enzyme - Google Patents

Method of producing an immunoligan d/paylo ad conjugate by means of a sequence-specific transpeptidase enzyme

Info

Publication number
SG11201507385YA
SG11201507385YA SG11201507385YA SG11201507385YA SG11201507385YA SG 11201507385Y A SG11201507385Y A SG 11201507385YA SG 11201507385Y A SG11201507385Y A SG 11201507385YA SG 11201507385Y A SG11201507385Y A SG 11201507385YA SG 11201507385Y A SG11201507385Y A SG 11201507385YA
Authority
SG
Singapore
Prior art keywords
immunoligan
paylo
conjugate
sequence
producing
Prior art date
Application number
SG11201507385YA
Other languages
English (en)
Inventor
Ulf Grawunder
Roger Renzo Beerli
Original Assignee
Nbe Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nbe Therapeutics Ag filed Critical Nbe Therapeutics Ag
Publication of SG11201507385YA publication Critical patent/SG11201507385YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/537—Protease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11201507385YA 2013-03-15 2014-03-14 Method of producing an immunoligan d/paylo ad conjugate by means of a sequence-specific transpeptidase enzyme SG11201507385YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361787371P 2013-03-15 2013-03-15
EP13159484.8A EP2777714A1 (en) 2013-03-15 2013-03-15 Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
US201461939754P 2014-02-14 2014-02-14
PCT/EP2014/055173 WO2014140317A2 (en) 2013-03-15 2014-03-14 Method of producing an immunoligand/payload conjugate

Publications (1)

Publication Number Publication Date
SG11201507385YA true SG11201507385YA (en) 2015-10-29

Family

ID=47900856

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201507385YA SG11201507385YA (en) 2013-03-15 2014-03-14 Method of producing an immunoligan d/paylo ad conjugate by means of a sequence-specific transpeptidase enzyme
SG10201903962PA SG10201903962PA (en) 2013-03-15 2014-03-14 Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201903962PA SG10201903962PA (en) 2013-03-15 2014-03-14 Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme

Country Status (13)

Country Link
US (4) US9872923B2 (he)
EP (2) EP2777714A1 (he)
JP (3) JP7213610B2 (he)
CN (3) CN109260478A (he)
AU (1) AU2014230129B2 (he)
BR (2) BR112015023589B1 (he)
CA (1) CA2903581A1 (he)
HK (1) HK1217296A1 (he)
IL (3) IL240893B (he)
MX (1) MX365547B (he)
SG (2) SG11201507385YA (he)
WO (1) WO2014140317A2 (he)
ZA (1) ZA201506005B (he)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
WO2014175690A1 (ko) 2013-04-25 2014-10-30 (재) 스크립스코리아 항체연구원 자가 절단 카세트를 포함하는 단백질 정제방법 및 이의 용도
WO2015165413A1 (zh) * 2014-04-29 2015-11-05 秦刚 一种新型的稳定型抗体药物耦联物及其制备方法和用途
JP6800154B2 (ja) 2014-12-17 2020-12-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 結合形成酵素の活性アッセイ
WO2016096787A1 (en) 2014-12-17 2016-06-23 F. Hoffmann-La Roche Ag Enzymatic one-pot reaction for double polypeptide conjugation in a single step using sortase
WO2016102679A1 (en) * 2014-12-23 2016-06-30 Nbe-Therapeutics Ag Binding protein drug conjugates comprising anthracycline derivatives
EP3256166A1 (en) 2015-02-09 2017-12-20 NBE Therapeutics AG Maytansine-drug conjugates of her- 2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
US10526344B2 (en) 2015-03-17 2020-01-07 Regeneron Pharmaceuticals, Inc. Amino acid acylation reagents and methods of using the same
WO2017050866A1 (en) 2015-09-25 2017-03-30 F. Hoffmann-La Roche Ag Novel soluble sortase a
JP6895953B2 (ja) 2015-09-25 2021-06-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ソルターゼａを利用してチオエステルを作製するための方法
EP3353201B1 (en) * 2015-09-25 2021-09-08 F. Hoffmann-La Roche AG Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
EP3353314A1 (en) 2015-09-25 2018-08-01 H. Hoffnabb-La Roche Ag Transamidation employing sortase a in deep eutectic solvents
EP3368577A1 (en) * 2015-10-30 2018-09-05 NBE-Therapeutics AG Anti-mesothelin antibodies
KR20180069067A (ko) 2015-10-30 2018-06-22 엔비이-테라퓨틱스 아게 안티-ror1 항체
SG11201806121PA (en) 2016-01-20 2018-08-30 Scripps Research Inst Ror2 antibody compositions and related methods
JP7000660B2 (ja) 2016-01-20 2022-02-04 ザ スクリプス リサーチ インスティテュート Ｒｏｒ１抗体組成物及び関連の方法
CN105925596A (zh) * 2016-02-23 2016-09-07 上海交通大学 基于内含肽的药用重组蛋白的合成方法
CN106397598B (zh) * 2016-02-23 2020-07-14 上海交通大学 多价多特异性抗体及免疫杂合蛋白的表达和制备方法
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
SG11201811292RA (en) 2016-06-17 2019-01-30 Magenta Therapeutics Inc Compositions and methods for the depletion of cells
EP3272864A1 (en) 2016-07-20 2018-01-24 Paul Scherrer Institut Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
SG11201906200WA (en) 2017-01-06 2019-08-27 Avidity Biosciences Llc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
SG10202102897PA (en) 2017-01-20 2021-04-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
US20210139579A1 (en) 2017-07-20 2021-05-13 Nbe-Therapeutics Ag Multispecific antibody product that binds to different ror1 epitopes
EP3655437A1 (en) * 2017-07-20 2020-05-27 NBE-Therapeutics AG Human antibodies binding to ror2
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
CN111133002B (zh) 2017-08-07 2024-05-24 恩比伊治疗股份公司 具有高体内耐受性的基于蒽环类药的抗体药物缀合物
CA3077213A1 (en) 2017-10-04 2019-04-11 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
CN107759699A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd30抗原的转基因t细胞及其制备方法与应用
AU2018378812A1 (en) 2017-12-06 2020-07-09 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
US12037370B2 (en) 2018-02-26 2024-07-16 Research Institute At Nationwide Children's Hospital Split-immunotoxins for boosting oncolytic virus toxicity
MX2020009469A (es) 2018-03-13 2021-01-29 Zymeworks Inc Conjugados de anticuerpo y farmaco anti-her2 biparatopicos y metodos de uso.
AU2019267011A1 (en) 2018-05-10 2020-10-29 Cis Biopharma Ag Biocompatible copolymer containing multiple active agent molecules
CN108593909A (zh) * 2018-05-23 2018-09-28 苏州立禾生物医学工程有限公司 一种定点标记免疫试剂的方法、标记免疫试剂及应用
US20210388112A1 (en) * 2018-07-09 2021-12-16 National University Corporation Kumamoto University Cyclic Single-Chain Antibody
EP3847188A1 (en) * 2018-09-03 2021-07-14 Technische Universität München A double peptide tag combining reversibility and flexible functionalization
US20220282231A1 (en) * 2018-09-30 2022-09-08 Shanghai Jiao Tong University Polypeptide composition
EP3636284A1 (en) 2018-10-11 2020-04-15 NBE Therapeutics AG Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
EP3647419A1 (en) 2018-11-02 2020-05-06 NBE Therapeutics AG Sortase f and its use in methods for conjugation
EP3898693A4 (en) 2018-12-21 2022-09-21 Avidity Biosciences, Inc. ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
WO2020188061A1 (en) * 2019-03-19 2020-09-24 Paul Scherrer Institut Transglutaminase conjugation method with a glycine based linker
CN114375297A (zh) 2019-06-06 2022-04-19 艾维迪提生物科学公司 Una亚酰胺及其用途
CN114375296A (zh) 2019-06-06 2022-04-19 艾维迪提生物科学公司 核酸多肽组合物及其用途
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
GB201914468D0 (en) 2019-10-07 2019-11-20 Crescendo Biologics Ltd Binding Molecules
AU2020376310A1 (en) 2019-10-30 2022-03-24 Cis Biopharma Ag Biocompatible polymeric drug carriers for delivering active agents
US12076400B2 (en) 2019-12-06 2024-09-03 Zymeworks Bc Inc. Methods of using a bispecific antigen-binding construct targeting HER2 in combination with CDK4/6 inhibitors for the treatment of breast cancer
CA3172111A1 (en) 2020-03-19 2021-09-23 Barbora MALECOVA Compositions and methods of treating facioscapulohumeral muscular dystrophy
MX2022011880A (es) 2020-03-27 2022-10-20 Avidity Biosciences Inc Composiciones y metodos para tratar distrofia muscular.
IL302017A (he) 2020-10-25 2023-06-01 Araris Biotech Ag אמצעים ושיטות ליצירת תצמידי נוגדן-לינקר
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
KR20230147105A (ko) 2021-01-28 2023-10-20 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 리가제 융합 단백질 및 그 응용
CA3213295A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
JP2024514174A (ja) 2021-04-14 2024-03-28 ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー． リンカー、コンジュゲート及びその用途
CN115369127A (zh) * 2021-05-18 2022-11-22 苏州有诺真生物科技有限公司 一种基于基因改造脊椎动物的携带通用定点偶联接口的抗体的制备方法
JP2024526764A (ja) 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド タンパク質凝集を防止する方法
WO2023014360A1 (en) * 2021-08-05 2023-02-09 Octagon Therapeutics, Inc. Treatment and diagnosis of immune disorders relating to aberrant immune cells
EP4384204A1 (en) 2021-08-13 2024-06-19 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
CN113777295B (zh) * 2021-09-15 2024-03-19 江南大学 用于检测肿瘤标志物pd-l1的高灵敏度量子点探针、制备方法及应用
AU2022345098A1 (en) 2021-09-16 2024-04-04 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
WO2023122347A2 (en) 2021-12-23 2023-06-29 Mirecule, Inc. Compositions for delivery of polynucleotides
CN118591394A (zh) * 2022-01-28 2024-09-03 启德医药科技（苏州）有限公司 抗体药物偶联物、药物组合物及用途
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024033362A1 (en) 2022-08-08 2024-02-15 Atb Therapeutics Humanized antibodies against cd79b
WO2024107765A2 (en) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932523B (en) 1992-04-10 1994-10-08 Res Dev Foundation Immunotoxins directed against cd33 related surface antigens
AU709988B2 (en) 1995-06-07 1999-09-09 Innogenetics N.V. Immunotoxins specific for CD80 and CD86 expressing cells
US7405276B2 (en) * 2000-11-01 2008-07-29 Elusys Therapeutics, Inc. Method of producing bispecific molecules by protein trans-splicing
DE10341812A1 (de) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005051976A2 (en) * 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
KR100918746B1 (ko) 2004-09-06 2009-09-24 교와 핫꼬 기린 가부시키가이샤 항 ａ３３ 항체
ES2539126T3 (es) * 2004-12-09 2015-06-26 Janssen Biotech, Inc. Inmunoconjugados anti integrina, métodos para su producción y su uso
DE102005061934A1 (de) * 2005-12-23 2007-06-28 Philipps-Universität Marburg Verfahren zur Herstellung eines chemisch modifizierten Proteins
WO2007108013A2 (en) 2006-03-22 2007-09-27 National Institute Of Immunology Novel bioconjugates as therapeutic agent and synthesis thereof
WO2008011157A2 (en) * 2006-07-20 2008-01-24 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
JP5618172B2 (ja) * 2007-01-05 2014-11-05 国立大学法人東京大学 抗ｐｒｇ−３抗体を用いる癌の診断および治療
LT2211904T (lt) 2007-10-19 2016-11-25 Seattle Genetics, Inc. Cd19 surišantys agentai ir jų panaudojimas
ES2547552T3 (es) 2008-02-01 2015-10-07 Genentech, Inc. Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos
JP2011517555A (ja) * 2008-03-14 2011-06-16 ジェネンテック， インコーポレイテッド 薬剤耐性に関連する遺伝的変異
WO2009132455A1 (en) * 2008-04-30 2009-11-05 Paul Xiang-Qin Liu Protein splicing using short terminal split inteins
ES2544971T3 (es) * 2008-05-13 2015-09-07 Genentech, Inc. Análisis de conjugados de fármacos y anticuerpos mediante espectrometría de masas con captura por afinidad basada en esferas
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
EP2391714B2 (en) 2009-01-30 2019-07-24 Whitehead Institute for Biomedical Research Methods for ligation and uses thereof
WO2010111018A1 (en) 2009-03-06 2010-09-30 Agensys, Inc. Antibody drug conjugates (adc) that bind to 24p4c12 proteins
WO2010115630A1 (en) 2009-04-08 2010-10-14 Deutsches Krebsforschungszentrum Amatoxin-armed target-binding moieties for the treatment of cancer
JP2012528112A (ja) 2009-05-28 2012-11-12 グラクソ グループ リミテッド 抗原結合タンパク質
EP2593469A4 (en) * 2010-04-20 2015-07-15 Whitehead Biomedical Inst MODIFIED PROTEINS AND POLYPEPTIDES AND USES THEREOF
ES2533710T3 (es) 2010-12-02 2015-04-14 Nerviano Medical Sciences S.R.L. Proceso para la preparación de derivados de morfolinil antraciclina
RU2636029C2 (ru) * 2011-02-01 2017-11-17 Генмаб А/С Человеческие антитела и конъюгаты антитело-препарат против cd74
WO2012142659A1 (en) * 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
WO2013022808A2 (en) * 2011-08-05 2013-02-14 The University Of Chicago Immunogenic protein conjugates and methods for making and using the same
KR20130046322A (ko) 2011-10-27 2013-05-07 한국외국어대학교 연구산학협력단 식중독 세균 Salmonella enterica 탐지용 탐침자 및 그를 포함한 DNA 칩
EP2852619A4 (en) * 2012-05-21 2016-04-27 Massachusetts Inst Technology TRANSLOCATION OF ARTIFICIAL CHEMICAL ENTITIES WITH ANTIGEN PROTECTIVE PORE AGAINST ANTHRAX
KR101718200B1 (ko) 2012-05-21 2017-03-21 제넨테크, 인크. 항-Ly6E 항체 및 면역접합체 및 사용 방법
SG11201407017WA (en) * 2012-06-04 2014-12-30 Irm Llc Site-specific labeling methods and molecules produced thereby
WO2014088928A1 (en) 2012-12-03 2014-06-12 President And Fellows Of Harvard College Methods for making targeted protein toxins by sortase-mediated protein ligation
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
WO2014175690A1 (ko) * 2013-04-25 2014-10-30 (재) 스크립스코리아 항체연구원 자가 절단 카세트를 포함하는 단백질 정제방법 및 이의 용도
JP2016520574A (ja) 2013-04-28 2016-07-14 秦剛 新規リンカー、その製造方法およびその応用

Also Published As

Publication number Publication date
WO2014140317A2 (en) 2014-09-18
BR112015023589B1 (pt) 2023-10-03
JP7481852B2 (ja) 2024-05-13
JP2016511279A (ja) 2016-04-14
NZ711762A (en) 2021-04-30
EP2777714A1 (en) 2014-09-17
HK1217296A1 (zh) 2017-01-06
SG10201903962PA (en) 2019-05-30
IL284979B (he) 2022-06-01
MX365547B (es) 2019-06-07
JP7213610B2 (ja) 2023-01-27
IL268423B (he) 2021-08-31
IL240893A0 (he) 2015-10-29
CN105142675B (zh) 2021-08-20
EP2968583A2 (en) 2016-01-20
AU2014230129B2 (en) 2019-03-28
BR122021025118B1 (pt) 2023-10-10
CN109260478A (zh) 2019-01-25
CA2903581A1 (en) 2014-09-18
CN113908291A (zh) 2022-01-11
BR112015023589A2 (pt) 2017-10-24
ZA201506005B (en) 2016-10-26
US20190262461A1 (en) 2019-08-29
US11986535B2 (en) 2024-05-21
WO2014140317A3 (en) 2014-12-24
IL240893B (he) 2019-08-29
US20160136298A1 (en) 2016-05-19
IL268423A (he) 2019-09-26
US20220378927A1 (en) 2022-12-01
MX2015012983A (es) 2016-04-04
JP2020089383A (ja) 2020-06-11
WO2014140317A8 (en) 2014-11-06
CN105142675A (zh) 2015-12-09
US20210015936A1 (en) 2021-01-21
US11364301B2 (en) 2022-06-21
AU2014230129A1 (en) 2015-09-24
AU2014230129A8 (en) 2016-04-14
IL284979A (he) 2021-08-31
JP2022130634A (ja) 2022-09-06
BR112015023589A8 (pt) 2022-03-08
US10864277B2 (en) 2020-12-15
US9872923B2 (en) 2018-01-23

Similar Documents

Publication Publication Date Title
IL284979A (he) שיטה לייצור אימונוליגנד/מטען קוניוגטי תוך שימוש באנזים טראנספפטידאז בעל ספציפיות לרצף
EP2940004A4 (en) PROCESS FOR PRODUCING OXIME
EP3006568A4 (en) Production method for tagatose
EP3042960A4 (en) Method for producing ambrein
EP2821392A4 (en) PROCESS FOR THE PREPARATION OF ACRYLNITRILE
PL2931937T3 (pl) Sposób wytwarzania układów nanocząstek metali
EP2837619A4 (en) PROCESS FOR THE PRODUCTION OF BETA-ALCOXYPROPIONAMIDE
IL237075A0 (he) שיטה להפקת נגזרת הקסאהידרופיורופראנול
SG11201403863YA (en) Method for producing high-molecular-weight polyisobutylene
EP3061352A4 (en) Method for producing kakiage
EP2824130A4 (en) PROCESS FOR PRODUCING POLYDIALKYLSILANE
EP3085232A4 (en) Co-crystal production method
SG11201601958WA (en) Method for producing butadiene
ZA201500438B (en) Method for producing microcarriers
EP3006133A4 (en) METHOD FOR MANUFACTURING STEEL TUBE
EP2843046A4 (en) USEFUL METHOD FOR ENZYMATIC CYCLIC DI-GMP SYNTHESIS
PL3017051T3 (pl) Sposób enzymatycznego wytwarzania 3-buten-2-onu
EP2980053A4 (en) BUTADIENHERSTELLUNGSVERFAHREN
IL230159A0 (he) שיטה לייצור של 2–אמינו–5–ציאנו–n,3–דימתילבנזאמיד
EP2927205A4 (en) PROCESS FOR PRODUCTION OF ALDEHYDE
SG11201501567QA (en) Method for producing 7-octenal
EP2868646A4 (en) PROCESS FOR PRODUCING ALDEHYDE
EP2975005A4 (en) METHOD FOR PRODUCING A SUBSTITUTE
EP2980065A4 (en) PROCESS FOR PRODUCING OXIME
EP3029145A4 (en) PROCESS FOR PRODUCTION OF METHACRYLYL-CoA